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Introduction
Prostate cancer is the second-leading cause of cancer death in men after 
lung cancer. The most common site of prostate metastasis is bone (84%), 
lymph node (10.6%), liver (10.2%), and thorax (9.1%), with 18.4% to multiple 
metastatic sites [1]. Prostate metastasis to the brain is rare, with less than 
1% documented cases from M.D. Anderson Cancer Center [2]. It is 
estimated that 1%-6% of prostate cancer metastasis is found in post mortem 
examination [3]. Parenchymal brain metastasis has a mean survival of 9.2 
months after discovery of brain metastasis [4]. Acute neurological symptoms 
of metastatic prostate cancer are observed with metastasis to the lumbar 
spine that impinge the spinal cord due to bony lesions. Symptoms of spinal 
cord compression, urinary retention, and hematuria are commonly seen. 
Conversely, meningioma is a slow-growing, non-infiltrative tumor that 
commonly presents with headaches, seizures, and focal neurologic deficits 
depending on location [5]. Prostate cancer is often diagnosed with 
neurological symptoms along with increasing prostate specific antigen. 
Metastatic prostate cancer presenting with headaches with normal levels of 
PSA is a rare presentation. We report a 68-year-old male who presented to 
the emergency department with a primary complaint of headache and falls 
that was initially diagnosed as meningioma with MRI and intraoperative 
frozen section that was later confirmed to be metastatic adenocarcinoma of 
the prostate on pathology.
Case Presentation
A 68-year-old male presented to the emergency department with headaches, 
right-sided weakness, and multiple falls for one-month duration. He was 
noted to have had 45 pounds of unintentional weight loss over the four 
months prior to presentation. Initial CT of the head showed a 3.2 cm right 
frontal mass with edema that was suspicious for meningioma, and the 
patient was admitted for further investigation and treatment. A metastatic 
workup was delayed by the urgent craniotomy due to mass effect at 
presentation. Preoperative workup showed anemia with hemoglobin of 9.7 
g/dl, alkaline phosphatase of 144 IU/L, and elevated PSA of 66.7 
ng/ml. Digital rectal exam revealed asymmetry of the prostate with an 
elevation of the left side of the gland but no discrete nodules. MRI of the 
brain showed a 2.8 cm right anterior frontal extra-axial mass with enhancing 
dural tail, likely representing meningioma. Additionally, MRI showed 
moderate vasogenic edema, raising suspicion for other histology such as 
oligodendroglioma (figure 1). Craniotomy was performed with an 
intraoperative frozen section initially reported as meningioma, but 
subsequently diagnosed as metastatic adenocarcinoma of the prostate on 
permanent pathology. Bone scan postoperatively showed increased uptake 
in multiple thoracic and lumbar vertebral bodies, sacrum, left humerus, right 
femur, and several bilateral ribs, suspicious for metastatic disease (figure 2.). 
There was also increased uptake in the right anterior skull, suggestive of 
postsurgical change. The CT abdomen and pelvis showed patchy sclerosis 
throughout the thoracolumbar spine and bony pelvis, suspicious for 
osteoblastic metastasis. Three weeks later, the patient presented to the 
hospital due to lower extremity edema. At this time repeat PSA was found to 
be 118.53, with total testosterone of 144 ng/dL. During the hospital stay 
Bicalutamide was initiated and then was followed by Degarelix in the clinic 
one week later. Leuprorelin was subsequently planned for one-month 
postoperatively and followed up with WBRT.
Figure 1: A. Preoperative transverse CT B. Preoperative transverse 
MRI C. Post operative transverse MRI
A. Preoperative CT head showing 3.2 cm right anterior frontal mass with 
edema. B. Transverse view of preoperative MRI showing 2.8 cm right 
anterior frontal extra-axial mass with enhancing dural tail, considered to 
likely be a meningioma. Moderate amount of vasogenic edema was 
considered unusual and raised considerations for other histology such as 
oligodendroglioma by radiology. C. Postoperative day-two MRI showing 
postsurgical changes and complete removal of mass.
Discussion
Differentiating primary brain lesions from metastatic prostate cancer can be 
challenging, especially when a solitary lesion is present. Specific MRI 
characteristics from metastatic prostate cancer have not been well 
established in literature; however, some reports describe hemorrhagic brain 
metastasis, mixed cystic, solid, or ring-like appearances on MRI. 
Hemorrhagic brain metastasis is more consistent with renal cell carcinoma, 
melanoma, choriocarcinoma, breast cancer, or thyroid cancer [6]. Of note, 
our patient had a negative head CT in December 2018. The rapid growth of 
the brain lesion also favors metastasis instead of meningioma as the cause. 
For our patient, the differential diagnosis of meningioma with edema was 
initially explored and then falsely positive confirmed with a frozen tissue 
sample biopsy. The initial sample did stain for meningioma.
Our patient’s PSA of 66.7 ng/ml qualifies for a bone scan for metastasis; 
however, the patient’s indolent course of prostate cancer was only detected 
at the time of extensive metastasis without causing lower urinary tract 
symptoms or other neurological symptoms usually seen with metastatic 
prostate cancer. Additionally, the patient’s previous PSA levels of 1.14 ng/ml 
in 2008, 0.91 ng/ml in 2011, and 1.18 ng/ml in 2013, along with the absence 
of symptoms, showed no indication for a bone scan. This patient's 
intraoperative frozen pathology was reported as meningioma, but later was 
documented as “cannot rule out malignancy.” Permanent pathology stained 
positive for PSA and PSAP, supporting metastatic adenocarcinoma of 
prostatic origin as the diagnosis.
Brain biopsy is not recommended in metastatic prostatic disease. Although 
histopathology is the confirmatory test of choice, it is unnecessary in patients 
with poor prognoses. In our patient, the diagnosis of brain metastasis was 
confirmed post resection of brain tumor. With headache as the presenting 
problem, a primary brain tumor was more probable than metastatic disease. 
Routine head imaging is also not performed in patients with prostate cancer. 
Historically, it has been reported that solitary brain metastasis has been 
treated with craniotomy with resection followed by radiation therapy with 
possible WBRT [7]. Androgen deprivation therapy with Bicalutamide and 
Degarelix was initiated with systemic chemotherapy to follow. Currently, 
Enzalutamide is the most commonly prescribed compound for treatment of 
metastatic castration-resistant prostate cancer. However, its use may be 
contraindicated in patients with brain metastasis since it potentiates seizures 
by crossing the blood-brain barrier. There are other antiandrogens, such as 
Abiraterone and Apalutimide, which are approved for use in metastatic 
prostate cancer, but with less passage through the blood-brain barrier, 
theorizing their limited use in brain metastasis [8]. Cabazetaxel has shown to 
improve passage through the blood-brain barrier compared to 
Docetaxel [9]. Chemotherapy will be followed up by WBRT recommended by 
radiology oncology.
Conclusions
Metastatic prostate cancer presenting as headaches due to metastasis to 
the brain is a rare finding that can occur at relatively low PSA levels. In 
patients of appropriate demographics and with abnormal digital rectal 
exams, differential diagnosis of prostate cancer must be explored even with 
imaging or histopathology that does not represent metastatic disease.
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